Study of RN0361 in Adult Subjects
Phase 1
Not yet recruiting
- Conditions
- Familial ChylomicronemiaHypertriglyceridemia
- Interventions
- First Posted Date
- 2024-06-24
- Last Posted Date
- 2024-06-24
- Lead Sponsor
- Ikaria Bioscience Pty Ltd
- Target Recruit Count
- 60
- Registration Number
- NCT06471543
- Locations
- 🇦🇺
Nucleus Network Melbourne, Melbourne, Victoria, Australia
the Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects in Adult Subjects With Elevated LDL-C
Phase 1
Completed
- Conditions
- To Reduce the LDL-C Level in Hypercholesteremia Patients
- Interventions
- First Posted Date
- 2023-11-15
- Last Posted Date
- 2025-04-03
- Lead Sponsor
- Shanghai Rona Therapeutics Co., Ltd.
- Target Recruit Count
- 32
- Registration Number
- NCT06132360
- Locations
- 🇨🇳
Peking University Third Hospital, Beijing, China
Adult Subjects With Elevated Low-Density Lipoprotein-Cholesterol to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects
Phase 1
Completed
- Conditions
- To Reduce the LDL-C Level in Hypercholesteremia Adult PatientsCombination for Subgroup High LDL-c Patients With Other Comorbidities
- Interventions
- Drug: RN0191 INJECTION
- First Posted Date
- 2023-06-15
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- Ikaria Bioscience Pty Ltd
- Target Recruit Count
- 32
- Registration Number
- NCT05905068
- Locations
- 🇦🇺
Nucleus Networks, Herston, Brisbane, Australia
© Copyright 2025. All Rights Reserved by MedPath